GlycoVaxyn´s goal is to improve human health through the development of novel bioconjugate vaccines using its proprietary glycoprotein technology. GlycoVaxyn´s technology paves the way for synthesizing bioconjugate material to levels previously unattainable and in a more cost effective manner.

News: GlycoVaxyn AG completes CHF 11.5 million Series A Financing. Former Aventis Pasteur President Michel Gréco appointed as chairman.